Recent updates on structural insights of MAO-B inhibitors: a review on target-based approach

link.springer.com/article/1...

MAO-B inhibitors, available currently in the market, carry various adverse effects such as dizziness, nausea, vomiting, lightheadedness, fainting, etc. So, there is an urgent need to develop new MAO-B inhibitors with minimum side effects. In this review, we have included recently studied compounds (2018 onwards). Agrawal et al. reported MAO-B inhibitors with IC50 0.0051 µM and showed good binding affinity. Enriquez et al. reported a compound with IC50 144 nM and bind with some critical amino acid residue Tyr60, Ile198, and Ile199. This article also describes the structure–activity relationship of the compounds and clinical trial studies of related derivatives. These compounds may be used as lead compounds to develop potent compounds as MAO-B inhibitors.

[curlscurls]

Thank you. A good reminder to keep an eye out for new better meds. I'm on rasagiline. It helps, but that nausea is annoying. It's probably adding some other items like light headedness, but it's hard to tell what's from what.